List view / Grid view
9 February 2015 | By The International Longevity Centre
With demand for NHS services already under pressure, new analysis by the International Longevity Centre – UK and supported by Engage Mutual, the over-50s life cover specialists, predicts the NHS may have to support up to one million more older people with serious illnesses within the next ten years...
6 February 2015 | By Janssen EMEA
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…
6 February 2015 | By Merck
The 5 year program was kicked off successfully in Africa, India and Indonesia and will further expand to other African and Asian countries in 2015...
6 February 2015 | By Public Health England
Flu vaccination remains important for other strains that still may circulate this winter...
6 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company will take part in the Leerink Swann Global Health Care Conference on Thursday, February 12, 2015, in New York...
6 February 2015 | By The Cochrane Library
The Cochrane Library recently published a review of chondroitin sulfate that confirms the efficacy and safety of this drug in the treatment of osteoarthritis...
5 February 2015 | By Eli Lilly and Company
New funding builds on a longstanding partnership to help Kenyans receive quality care...
5 February 2015 | By BIOTRONIK
BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced that patient enrollment for the BIOFLOW-IV study has been completed...
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...
4 February 2015 | By AstraZeneca
AstraZeneca announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City...
4 February 2015 | By Genmab
Genmab A/S today announced preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma conducted by its collaboration partner Janssen Biotech...
4 February 2015 | By GlobalData
The French pharmaceutical market is forecast to grow at a tepid Compound Annual Growth Rate (CAGR) of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, restricted by an increasing focus on generic drugs, according to research and consulting firm GlobalData...
3 February 2015 | By Lilly Diabetes
Today Lilly Diabetes announced its support of the American Diabetes Association (Association) summer camp program by donating $92,000 for camp scholarships...
3 February 2015 | By AYOXXA Biosystems / SERI
AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools...
3 February 2015 | By Pierre Fabre Pharmaceuticals
Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial…
